NCT02704559已完成1 期
Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects
Daewoong Pharmaceutical Co. LTD.1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2015年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Peak Plasma Concentration (Cmax)
研究概览
简要总结
A randomized, open-label, oral dose, crossover study to explore drug-drug interactions between DWC20155 and DWC20156 in healthy subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Accepts healthy volunteers.
排除标准
- •Who has allergy to investigational product
研究组 & 干预措施
Study effect of DWC20155 on DWC20156 PK
Experimental
To study effect of DWC20155 on DWC20156 PK
干预措施: DWC20155 (Drug)
Study effect of DWC20156 on DWC20155 PK
Experimental
To study effect of DWC20156 on DWC20155 PK
干预措施: DWC20156 (Drug)
结局指标
主要结局
Peak Plasma Concentration (Cmax)
时间窗: 0~24hr
Area under the plasma concentration versus time curve (AUC)
时间窗: 0~24h
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy VolunteersHealthyNCT02947139Daewoong Pharmaceutical Co. LTD.53
已完成
1 期
Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy VolunteersHealthyNCT02952755Daewoong Pharmaceutical Co. LTD.45
Unknown
1 期
Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy VolunteersHealthyNCT03005223Daewoong Pharmaceutical Co. LTD.52
已完成
1 期
Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult SubjectsInfection, Human Immunodeficiency VirusNCT02082808ViiV Healthcare12
已完成
1 期
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without DacarbazineAdvanced MelanomaNCT00542893Genta Incorporated